
Opinion|Videos|March 18, 2024
Current Front-Line Targeted Treatments in Ph+ ALL
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
2
ICYMI: Highlights From SPD 2025
3
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
4
Digital Innovation and New Drugs Converge to Transform CRM Care
5











































